@article{soumya mula_2019, 
  title={SEBELIPASE ALFA NEW THERAPY OF CHOICE FOR WOLMAN DISEASE}, 
  DOI={10.5281/zenodo.3381567}, 
  abstractNote={<em>Lysosomal enzyme activity deficiency(LAL-D) is a rare disorder of cholesterol metabolism of cellular steroid alcohol and for the physiology of lipoprotein diseases. When deficient in lysosomal acid </em><em>lipase</em><em>( </em><em>LAL), the enzyme results in deposited with steroid alcohol and triglycerides in a specific number of tissues. Future clinical results of adult and LAL patient medical care were assessed mainly using advantages of Sebelipase Alfa medical services that improve quality and life by examining several papillary diseases. Square measures were used to evaluate the clinical results of Sebelipase Alfa medicine. There is no cure, in particular, ongoing trails to enhance the sebelipase generation. Supportive management with lipid-modifying agents does not ameliorate disease progression. Hematopoietic stem cell transplantation as a curative measure in infantile disease has mixed success and is associated with inherent risks , complications and liver transplantation complexity by comparing the methods. Sebelipase was proved to be long term therapy for affected individuals. </em><em>(Kanuma) is the human LAL protein recombinant and the first LAL-D treatment was enzyme replacement therapy. In infants with rapid progressive LAL-D adults and children with later -onset LAL-D, clinical studies were undertaken.There is no cure to particular disease but it can increase life expectancy of affected patient.</em> <strong>Key Words</strong>: <em>lysosomal acid lipase, </em><em>cholesteryl esters</em><em>, triglycerides, calcification, Kanuma</em>}, 
  publisher={Zenodo}, 
  author={Soumya Mula, Harinath Jolapuram}, 
  year={2019}, 
  month={Aug}
  }